Novartis AG is a global healthcare company that specializes in developing and manufacturing innovative pharmaceuticals and medical products. The company focuses on research-driven solutions in various therapeutic areas, including oncology, cardiology, immunology, and neuroscience, among others. Novartis is committed to improving patient health by providing high-quality medications and treatments, and it invests significantly in research and development to discover and deliver new therapies. In addition to its pharmaceutical division, Novartis also offers generics and biosimilars through its Sandoz division, making healthcare more accessible to patients worldwide. Read More
Shanghai, China, September 2, 2025 -- Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a vital gateway for global enterprises. With preparations for the 8th CIIE well underway, the expo is set to once again showcase innovation, foster cooperation, and expand access to the Chinese dynamic market.
Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a vital gateway for global enterprises. With preparations for the 8th CIIE well underway, the expo is set to once again showcase innovation, foster cooperation, and expand access to the Chinese dynamic market.
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has escalated significantly through 2025, with both nations frequently adjusting and reinstating tariffs, creating a tangled web of
Novartis (NVS) offers a strong 3.55% dividend yield, backed by consistent payouts, solid profitability, and financial health—ideal for stable income investing.
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and
Novartis AG-SPONSORED ADR (NVS) is a top pick for value investors, offering solid fundamentals, strong profitability, and a 3.76% dividend yield, all at an attractive valuation.
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.
Novartis' ianalumab showed significant disease activity improvement in two Phase 3 Sjögren's trials, supporting plans for global health authority filings.
